Briefing
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
MRD analysis of the randomized GLOW trial of fixed-duration ibrutinib-venetoclax vs chlorambucil-obinutuzumab in older or comorbid first-line CLL, relating MRD status to PFS. Level 2 (MRD analysis of an RCT; therapy was fixed-duration, not MRD-guided).
- Design: paper
- Assay: MRD after fixed-duration I+V (not MRD-guided)